A new international study finds that introducing an increased intensity of chemotherapy in children with severe Langerhans cell histiocytosis (LCH) can reduce the mortality rate for this disorder by as much as 20 percent when the patient demonstrates a rapid response to such treatment.
The study, published in the March 1 edition of Blood, the journal of the American Association of Hematology, is the second in a series of international randomized clinical trials for Langerhans cell histiocytosis coordinated by the Histiocyte Society. The LCH clinical trial series are the first-ever randomized clinical trials for the treatment of LCH.
“The incidence of this particular disorder is so rare, without the cooperation of researchers and participants across the globe, the trial could not have been conducted on a large enough scale to see such positive, and definitive outcomes,” noted senior author Stephan Ladisch, MD, Bosworth Chair for Cancer Biology and Director of the Center for Cancer and Immunology Research at Children's National Medical Center. “The value of international collaborations such as this is incalculable to the research of so-called ‘orphan diseases' that receive little government funding support, but still have a significant effect on the lives of children around the world.”
The trial induced a rapid response to the application of chemotherapy—involving prednisone, vinblastine, and for some participants, the addition of etopisode. As a result, the research team observed a statistically significant improved prognosis for children with multi-system LCH. Study leaders observed this significant effect in both study groups of the second clinical trial.